slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 6,421-6,450
Pages 395
Rows per page 30
Slide function
6,421-6,450 of 11,828
13
The slide uses a Land & Expand framework to categorize key business performance indicators.Doximity | Investor Presentation Deck | 18 slides · Doximity
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Includes CAGR metrics for both revenue and EBITDA.Doximity | Investor Presentation Deck | 18 slides · Doximity
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
Includes statistical significance markers (p-values) and sample sizes (n).Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
29
The chart shows a significant drop in viral load starting around day 14, stabilizing at a low level from day 145 onwards.Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
06
Includes footnote regarding currency exchange rate for the option exercise payment.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
20
Includes comparative data against Mogamulizumab (MAVORIC trial) and visual evidence of skin improvement.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
21
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes photographic evidence of hair regrowth over 21 days and a bar chart showing fold reduction of NKG2D marker.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
13
The slide combines a biological pathway diagram (mechanism of action) with a clinical trial summary table.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
18
Swimmer plot visualization of clinical trial data (Trial LXH254X2102).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
19
The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
20
Swimmer plot visualization of clinical trial data.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
28
Data shows tumor volume over time for various treatment groups including monotherapy and combinations.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
29
Includes waterfall plot (left) and swimmer plot (right) with specific response rates and disease control rates.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
33
Data presented as tumor volume over time (days) with error bars representing SEM.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
39
The chart shows a statistically significant (***) improvement in survival for the ERAS-801 group compared to the control and other standard-of-care inhibitors.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
40
The slide presents four separate survival plots (HK301, GS025, HK336, GS187) comparing vehicle control to ERAS-801 treatment.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
41
The slide uses a waterfall plot to show individual model responses, with a heatmap below for patient characteristics (recurrence, sex, methylation status).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
50
The chart displays individual patient responses categorized by dose level, with a list of specific notable responses on the right.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
51
The chart displays patient-level data including cancer type, mutation, weekly dose, and response status (Partial Response, Stable Disease, Progressive Disease).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
06
Includes seller census data and growth metrics.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a process flow at the bottom to illustrate the impact of the initiative.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
11
Etsy | Investor Presentation Deck | 34 slidesEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
The slide highlights efficiency gains by showing marketing spend as a percentage of revenue decreasing to 26% in Q2 23.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
14
The slide uses two charts to demonstrate marketing efficiency and buyer behavior evolution.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
Etsy | Investor Presentation Deck | 34 slidesEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
18
The chart shows negative growth rates that are trending toward zero, which the company frames as 'the right direction'.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit